peptideInjectableNot FDA-approvedResearch chemicalSold as a research chemical with no approved human medical useAnalytical work has flagged it in black-market doping products
Follistatin-344Benefits, Dosage & Interactions
Also known as: FST-344
Follistatin-344, also known as FST-344, is a naturally occurring protein that belongs to the follistatin family, primarily recognized for its ability to bind and inhibit members of the transforming growth factor-beta (TGF-β) superfamily, particularly myostatin. Research on Follistatin-344 focuses on muscle and strength.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Limited — Human observational or case data only — no randomized trials.
Evidence strengthLimited · 2/4
PreclinicalStrong human evidence
Human observational or case data only — no randomized trials.
Plasma half-life
Not established
Default unit
mcg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Follistatin-344 in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Follistatin-344 entry is written from. Each number matches an inline marker above.
- [1]Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic PerformanceMendias CL, Awan TM · Sports Medicine (Auckland, N.Z.) · 2026 · Peer-reviewed · PMID 41966639
- [2]Detection of black market follistatin 344Reichel C, Gmeiner G, Thevis M · Drug Testing and Analysis · 2019 · Peer-reviewed · PMID 31758732
- [3]Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case seriesDağ U, Çağlayan M, Öncül H, Alakuş MF · International Ophthalmology · 2020 · Peer-reviewed · PMID 32671599
- [4]The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigsChang F, Fang R, Wang M, Zhao X, Chang W, Zhang Z, Li N, Meng Q · Transgenic Research · 2017 · Peer-reviewed · PMID 27787698
How to track Follistatin-344 doses
Follistatin-344 is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Follistatin-344 is stored as a concentration rather than a guess. DoseRoutine converts that into mcg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mcg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Follistatin-344 comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
Review Follistatin-344 alongside your logged metrics and any relevant blood work every few weeks before changing the dose, so the change is a response to data rather than to a good or bad day.
What to log each time
- Dose in mcg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
What is Follistatin-344 studied for?
What is Follistatin-344?
Follistatin-344, also known as FST-344, is a naturally occurring protein that belongs to the follistatin family, primarily recognized for its ability to bind and inhibit members of the transforming growth factor-beta (TGF-β) superfamily, particularly myostatin. Myostatin is a protein that normally limits muscle growth; by inhibiting myostatin, FST-344 may promote increased muscle mass and strength. This peptide is a synthetic version of the human follistatin protein, specifically a splice variant that contains 344 amino acids. Research into Follistatin-344 aims to understand its potential therapeutic applications in conditions characterized by muscle wasting, such as muscular dystrophy and sarcopenia, and its possible use in enhancing athletic performance. (PubChem)
What does the research say about Follistatin-344?
Tap a section to expand.
The primary mechanism of action for Follistatin-344 involves its potent antagonistic effect on myostatin. Myostatin (Growth Differentiation Factor 8 or GDF-8) is a negative regulator of muscle growth, meaning it limits the size of muscle fibers and the overall potential for muscle development. Myostatin achieves this by signaling through activin receptors, which ultimately suppresses myogenesis (the formation of muscular tissue). Follistatin-344 directly binds to myostatin, as well as other TGF-β superfamily members like activin, preventing them from binding to their receptors. By sequestering myostatin and activin, FST-344 effectively neutralizes their activity, thereby removing the inhibitory signals that restrict muscle growth and differentiation. This allows for an increase in muscle cell proliferation and differentiation, leading to hypertrophy (increase in muscle cell size) and hyperplasia (increase in the number of muscle cells). (DrugBank)
Research into Follistatin-344 primarily explores its potential benefits related to muscle growth and conditions involving muscle wasting. The key areas of interest include:
* **Enhanced Muscle Hypertrophy:** By inhibiting myostatin, FST-344 may allow for increased protein synthesis and satellite cell activation, leading to a significant increase in muscle fiber size and overall muscle mass. This effect has been observed in animal models. (DrugBank)
* **Prevention and Treatment of Muscle Wasting Conditions:** Due to its myostatin-inhibiting properties, Follistatin-344 is being investigated for its potential to counteract muscle loss in conditions such as muscular dystrophy, sarcopenia (age-related muscle loss), cachexia (wasting syndrome), and other situations where muscle mass is compromised. (PubChem)
* **Improved Muscle Repair and Regeneration:** By promoting an environment conducive to muscle cell proliferation and differentiation, FST-344 may also play a role in accelerating muscle repair after injury. (DrugBank)
* **Potential for Fat Loss:** Some preclinical studies suggest that increased muscle mass, driven by myostatin inhibition, can lead to a higher basal metabolic rate, potentially contributing to a reduction in body fat. However, this is largely an indirect effect and not a primary mechanism. (PubChem)
It is important to note that most of these potential benefits are derived from preclinical studies and animal models. Human clinical trials are ongoing to fully ascertain the efficacy and safety of Follistatin-344 for these applications.
Scientific evidence for Follistatin-344 largely stems from *in vitro* studies and animal models. Murine models have shown significant increases in muscle mass and strength following administration of follistatin, including instances where myostatin-deficient mice exhibit a 'double-muscling' phenotype. For example, research published in *Nature* (though not specifically on FST-344 but on myostatin inhibition via follistatin) demonstrated that interfering with myostatin signaling in adult mice led to substantial increases in muscle mass. (PubChem)
Studies in various animal models, including non-human primates, have explored the use of gene therapy to express follistatin locally or systemically, resulting in notable muscle growth and improved muscular function. While these studies provide strong evidence for the biological activity of follistatin in muscle regulation, it's crucial to differentiate these from direct studies on the synthetic peptide Follistatin-344 in humans. (DrugBank)
Preclinical data support the hypothesis that Follistatin-344 can effectively neutralize myostatin and activin, leading to muscle hypertrophy. Human clinical trials for Follistatin-344, especially for direct muscle-building applications in healthy individuals, are limited or in very early stages. Most human research on follistatin derivatives aims at treating specific muscle-wasting diseases. (NIH ODS)
As Follistatin-344 is a research peptide and not approved for human use by regulatory bodies like the FDA or EMA, comprehensive data on its side effects in humans are limited. Based on preclinical studies and the known physiological roles of follistatin and myostatin, potential side effects might include:
* **Immune Response:** As a protein, there's a theoretical risk of an immune response, including antibody formation, which could neutralize the peptide or trigger allergic reactions.
* **Cardiovascular Effects:** Alterations in muscle mass could indirectly impact cardiovascular function, though direct effects are not well-established.
* **Impact on other TGF-β Superfamily Members:** While primarily targeting myostatin, follistatin also binds to and inhibits other TGF-β superfamily members like activins. Modulating these pathways could lead to unintended physiological effects, as activins play roles in various processes, including reproduction, inflammation, and immune regulation.
* **Gastrointestinal Disturbances:** As with many injectable compounds, localized irritation at the injection site or systemic gastrointestinal discomfort could occur.
* **Joint and Connective Tissue Changes:** Rapid muscle growth might put additional stress on tendons, ligaments, and joints, potentially increasing the risk of injury if not managed with appropriate resistance training and recovery.
Since this compound is not thoroughly clinically studied in humans for general use, the full spectrum of potential side effects, especially long-term effects, remains unknown. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Specific warnings for Follistatin-344 are scarce due to its status as a research chemical not approved for human therapeutic use. However, general warnings applicable to any experimental peptide or substance that significantly alters natural physiological processes would apply:
* **Lack of Human Safety Data:** There is a significant paucity of robust, peer-reviewed human clinical trial data on the safety and long-term effects of Follistatin-344. Most available information comes from animal studies or *in vitro* research.
* **Potential for Unintended Biological Effects:** FST-344 modulates fundamental growth pathways. Uncontrolled or chronic modulation of such pathways could lead to unforeseen consequences beyond muscle growth, potentially affecting other organs or biological systems.
* **Risk of Immunogenicity:** Administration of a peptide carries the risk of stimulating an immune response, leading to antibody development against the peptide, which could reduce its efficacy or cause adverse reactions.
* **Contamination and Purity Issues:** As Follistatin-344 is often acquired from sources not regulated by pharmaceutical standards, there is an inherent risk of contamination or incorrect product purity and composition.
* **Ethical and Legal Concerns:** Use of research compounds outside of a controlled research setting raises ethical questions and may have legal implications depending on jurisdiction.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Given the limited human clinical data for Follistatin-344, definitive contraindications are not established. However, based on its mechanism of action and general biomedical principles, potential contraindications would include:
* **Pregnancy and Lactation:** The effects on fetal development or infants are unknown and could be detrimental. It is highly contraindicated in these populations.
* **Children and Adolescents:** Due to the impact on growth and development, Follistatin-344 would be contraindicated in individuals whose skeletal and endocrine systems are still maturing.
* **Pre-existing Medical Conditions:** Individuals with any pre-existing medical conditions, particularly those involving growth disorders, cancer (due to the potential for influencing cell proliferation pathways), hormonal imbalances, or cardiovascular issues, should avoid this compound.
* **Allergies:** Individuals with known allergies to peptides or any excipients in the formulation should avoid use.
* **Kidney or Liver Impairment:** The metabolism and excretion pathways of Follistatin-344 are not fully characterized in humans. Individuals with compromised kidney or liver function may be at higher risk for accumulation or adverse effects.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Due to the absence of extensive human clinical trials and comprehensive safety data, specific interactions between Follistatin-344 and other compounds are largely unknown. Therefore, a conservative approach of avoiding mixing with most other substances is prudent. Potential areas of concern without direct evidence include:
* **Other Growth Factors/Peptides:** Combining FST-344 with other compounds that influence growth hormone, IGF-1, or other growth-related peptides could theoretically lead to unpredictable synergistic or antagonistic effects, potentially increasing the risk of adverse outcomes.
* **Immunosuppressants/Immunostimulants:** Given the theoretical potential for immune response or modulation, co-administration with drugs affecting the immune system should be approached with extreme caution.
* **Hormonal Therapies:** As FST-344 impacts growth pathways, combining it with other hormonal therapies or steroids could lead to complex and potentially dangerous interactions given the broad physiological roles of these pathways.
* **Medications for Chronic Diseases:** Individuals on chronic medication for conditions like diabetes, cardiovascular disease, or cancer should absolutely avoid Follistatin-344 due to the unknown interaction profiles and potential for exacerbating underlying conditions or interfering with established treatments.
Always discuss any experimental compounds with a qualified healthcare professional, especially if you are taking other medications or supplements. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
The typical timing for Follistatin-344 administration is user-directed and must be set by a licensed clinician. It is typically administered via injection, and the frequency and duration of administration would depend on the specific research protocol or guided by expert medical advice given its experimental nature. There are no standardized or FDA/EMA-approved dosing guidelines. Meals do not typically influence the absorption or efficacy of injectable peptides, hence it can be taken relative to food. The compound has a half-life of approximately 48 hours.
What interacts with Follistatin-344?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Follistatin-344
Follistatin-344 is a research peptide. It is also known as FST-344. The references summarized come from NIH and PubMed records, FDA labeling where it exists, and Mayo Clinic patient material.
Follistatin-344 is commonly discussed in the context of supporting muscle. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Follistatin-344, it is typically administered by injection and it is typically taken null. Always follow the specific dose your clinician or the product label prescribes.
Follistatin-344 carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
As a peptide, Follistatin-344 can overlap with other supplements, prescription medicines, hormones and peptides. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Follistatin-344 with no sign-up.
Whether Follistatin-344 fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Follistatin-344. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for Follistatin-344 varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of Follistatin-344 depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Follistatin-344 the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Follistatin-344?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series(opens PubMed in a new tab)Int Ophthalmol · 2020 · PMID 32671599 · https://pubmed.ncbi.nlm.nih.gov/32671599/
- 2.The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs(opens PubMed in a new tab)Transgenic Res · 2017 · PMID 27787698 · https://pubmed.ncbi.nlm.nih.gov/27787698/
Verify at
Publisher search links for Follistatin-344. These are places to check the information — they are not citations, so they are not numbered.
- PubChem(publisher search, opens in a new tab)National Center for Biotechnology Information · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Follistatin-344?
Plain-text summary, safe to quote verbatim:
Follistatin-344, also known as FST-344, is a naturally occurring protein that belongs to the follistatin family, primarily recognized for its ability to bind and inhibit members of the transforming growth factor-beta (TGF-β) superfamily, particularly myostatin. Research on Follistatin-344 focuses on muscle and strength.
Source: DoseRoutine — https://doseroutine.com/library/follistatin-344
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Follistatin-344 — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/follistatin-344
What compounds are similar to Follistatin-344?
Others in the peptide category or studied for the same goals.
Which goals is Follistatin-344 used for?
Other compounds studied for the same benefits as Follistatin-344.
Continue exploring
See every compound DoseRoutine catalogs for these goals.